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Abstract
Good quality clinical trials are essential to inform the best cystic fibrosis (CF) management and care,
by determining and comparing the effectiveness of new and existing therapies and drug delivery
systems. The formal inclusion of quality of life (QoL) as an outcome measure in CF clinical trials is
becoming more common. Both an appropriate QoL measure and sound methodology are required
in order to draw valid inferences about treatments and QoL. A review was undertaken of
randomised controlled trials in cystic fibrosis where QoL was measured. EMBASE, MEDLINE and
ISI Web of Science were searched to locate all full papers in the English language reporting
randomised controlled trials in cystic fibrosis, published between January 1991 and December
2004. All Cochrane reviews published before December 2004 were hand searched. Papers were
included if the authors had reported that they had measured QoL or well being in the trial. 16 trials
were identified. The interventions investigated were: antibiotics (4); home versus hospital
administration of antibiotics (1); steroids (1); mucolytic therapies (6); exercise (3) and pancreatic
enzymes (1). Not one trial evaluated in this review provided conclusive results concerning QoL.
This review highlights many of the pitfalls of QoL measurement in CF clinical trials and provides
constructive information concerning the design and reporting of trials measuring QoL.
Review
Cystic fibrosis and its management
Cystic fibrosis (CF) is a life threatening, recessively inher-
ited disease caused by defects in a single gene on chromo-
some 7 [1,2]. The faulty gene causes an increased
production of thickened secretions in most organs of the
body. In the respiratory tract this impairs the clearance of
micoorganisms resulting in recurrent infections, inflam-
mation, lung damage and eventually death from respira-
tory failure. In the pancreas, the pancreatic exocrine cells
become blocked, leading to the failure of the pancreas to
produce digestive enzymes causing the maldigestion and
malabsorption of nutrients. Current median survival is
more than 30 years [3,4], and half of children born in the
1990's are expected to survive to more than 40 years [5].
With increasing age, however, a high proportion of people
develop diabetes mellitus, and some patients endure a
variety of complications including pneumothorax, hae-
moptysis, chronic liver disease and osteoporosis.
Cystic fibrosis has an extraordinarily demanding treat-
ment regimen. The management of respiratory disease is
directed at identifying and eradicating bacterial infection
from the airways. Preventing chronic infection with Pseu-
domonas aeruginosa can slow down the deterioration in
lung function and improve survival [6,7]. Respiratory
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disease is treated with antibiotics, mucolytics, bronchodi-
lators and corticosteroids. Additionally, twice daily chest
physiotherapy and an exercise regimen aid the clearance
of respiratory secretions. The management of gastrointes-
tinal symptoms hinges on the maintenance of body
weight and, therefore, a high energy, high fat diet is pre-
scribed. To aid the absorption of nutrients, oral pancreatic
enzymes are taken with food. Malnutrition is managed
with fat-soluble vitamins and oral feed supplements and/
or where required, nocturnal enteral feeding. CF-related
diabetes requires insulin, and further therapies are
required to deal with other complications.
The importance of clinical trials in CF
Effective treatments, in particular those that are acceptable
to patients, are crucial to slow down disease progression.
Good quality clinical trials are essential to generate evi-
dence to inform CF management, by determining and
comparing the effectiveness of therapies and drug delivery
systems. Often, the ultimate aim of treatment is to
increase survival, but it is impractical for trials involving
younger patients to have survival as a primary end-point.
Instead investigators opt for proxy outcome measures. The
progression of CF disease is usually evaluated by changes
in lung function; forced expiratory volume in 1 second
(FEV1) being the typical primary outcome measure. It has
been commonplace for researchers to conclude that
because treatments had benefits for clinical outcomes
there must also have been benefits for QoL. There are
many such assertions in the literature without empirical
evidence, however, the formal inclusion of QoL as an out-
come measure in CF clinical trials is now increasing.
The quality of clinical trials
There has been considerable concern about the quality of
reporting of randomised controlled trials (RCTs). Poorly-
designed trials are likely to produce biased results and
hence misinformed decision-making. Inadequate report-
ing means that readers are unable to assess the quality of
the design of an RCT and are consequently unable to
assess the usefulness of the conclusions. The CONSORT
statement [8] was devised to improve the quality of
reporting of RCTs. Both an appropriate QoL measure and
sound methodology are required for valid inferences
about treatments and QoL. With this in mind a review was
undertaken of RCTs in cystic fibrosis where QoL was
measured.
The identification of papers
EMBASE, MEDLINE and ISI Web of Science were searched
to locate all full papers in the English language reporting
RCTs in cystic fibrosis, published between January 1991
and December 2004. Papers were located that included
'cystic fibrosis' and 'quality of life' or 'health status' in the
title, abstract or keywords, and these were hand-searched
for all randomised controlled trials. Extra searches on
'well-being' were carried out in databases where this key
word was accepted. Papers were included if authors
reported that they had measured QoL or well-being. All
Cochrane reviews [9] published before December 2004
were hand-searched. Only trials exclusively on people
with cystic fibrosis were included i.e. trials were omitted
where some of the subjects had cystic fibrosis. Papers were
omitted which described a study on a subset of subjects in
an RCT, but secondary analyses of RCTs where the pri-
mary findings had previously been published were
included. Each author undertook searches and reviews
independently. A summary sheet was used to record the
following: rationale for measuring QoL; choice of QoL
instrument, quality of scale description and scoring meth-
ods; sample size justification; quality of summary statis-
tics for QoL and analysis; discussion of the clinical
importance of QoL findings and general methodological
quality in relation to QoL
A total of 16 trials were identified. The interventions
investigated were: antibiotics (4); home versus hospital
administration of antibiotics (1); steroids (1); mucolytic
therapies (6); exercise (3); and pancreatic enzymes (1).
The trials, with patient characteristics, are summarised in
Tables 1 and 2. Table 1 presents a summary of RCTs eval-
uating antibiotics and steroids. Table 2 summarises the
RCTs evaluating mucolytic therapies, exercise and pancre-
atic enzymes.
Review of CF trials that have measured QoL
Antibiotic therapy
One of the most important therapies for CF is antibiotics
aimed at preventing, eradicating and controlling respira-
tory infection. Pseudomonas aeruginosa (PA) is the most
prevalent infection [10], and the prognosis of chronically
infected patients is considerably worse [11]. It is also
known that pulmonary exacerbations have a strong nega-
tive impact on QoL in CF [12], therefore an effective anti-
biotic should be able to demonstrate improvements in
QoL. Of the four antibiotic trials that reported measuring
QoL in CF (as a secondary outcome) one evaluated
tobramycin and the other three assessed azythromycin.
Tobramycin's mode of delivery is appealing to patients as
it is nebulised, delivering high concentrations of the drug
to the site of infection; making the treatment less complex
and time-consuming than by intravenous administration.
Ramsey et al. [13] conducted a placebo-controlled RCT of
inhaled tobramycin and concluded that the drug
improved lung function. Quittner et al. [14] reported on
QoL from a secondary analysis of this work. Patients were
assigned to receive either tobramycin (300 mg twice daily)
or placebo for three treatment cycles, with each cycle con-
sisting of 28 days on the drug followed by 28 days off theHealth and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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drug. QoL was assessed only at the end of each treatment
period (28 days on the drug) using a non-validated, three
point, uni-dimensional global rate of change question-
naire. Patients (or parents of some children) and physi-
cians reported whether the patient's condition remained
unchanged, improved or deteriorated. The authors
reported that a greater number of patients receiving
tobramycin felt better at the end of each treatment cycle.
There is evidence that patients taking the drug were more
likely to report an improvement in their condition after
each period of treatment. However, how 'feeling better or
worse' would impact on different aspects of a person's
QoL is unknown and the authors themselves suggest that
evaluation with CF-specific QoL scales would be benefi-
cial. It is also unclear how many children's ratings or
parental proxy ratings were included in the analysis. Pre-
treatment data were not collected so it is unknown what
happened in the periods off treatment. Without this infor-
mation, and the magnitude of all changes, it is impossible
to deduce what the overall changes would have been if
QoL had been measured at baseline and at 6 months.
Macrolide antibiotics are unable to kill PA  but it is
thought that they may reduce the activity of the bacteria
[15]. Azythromycin has become a focus of interest in CF
because it is possible that it reduces sputum viscosity and
airway adhesion of PA [16]. If a drug can reduce bacterial
activity and inflammation, and enable sputum to be
expectorated more easily, it may be expected to improve
QoL. If it can also be administered orally, rather than
being given intravenously or via a nebuliser, its potential
impact on QoL may be considerable. Equi et al. [17]
undertook a 15 month, randomised, double blind, pla-
cebo-controlled crossover trial. Patients received either
azythromycin (bodyweight <40 kg = 250 mg daily; >40 kg
= 500 mg daily) or placebo for six months. This was fol-
lowed by a two month washout period prior to the treat-
ments being crossed over. Lung function was the primary
outcome measure. QoL was one of several secondary out-
comes and was measured using the Quality of Well Being
Scale (QWB). The scale is not described in the paper but it
is a utility instrument, typically administered by inter-
view. It generates a single score by summing the scores of
the three subscales: mobility, physical activity and social
activity. The authors reported an improvement in FEV1 for
Table 1: Summary of RCTs in CF measuring QoL: antibiotics and steroids
Authors Brief description Sample QoL scale used Authors' main 
conclusion
Authors' conclusion 
about QoL outcome
ANTIBIOTICS
Quittner et al. [14]
Secondary analysis of 
Ramsey et al. [13]
Secondary analysis of 
RCT.
Tobramycin versus 
placebo in 3 cycles
n = 520 (age >= 6 years) 
(n = 499 for QoL)
mean age 21 years FEV1 
25% to 75%
Non-validated 3-point 
scale (better/no change/
worse) primary 
outcome
Tobramaycin improved 
lung function (not 
reported here)
Tobramycin associated 
with improved QoL
Equi et al. [17] Azithromycin (250 gm 
or 500 gm dependent 
on weight) vs placebo; 
crossover design
n = 41 (age 8–18 years) 
median FEV1 = 61% 
(range 33% to 80%)
QWB Significant improvement 
in FEV1 compared with 
placebo, but not FVC or 
mid-expiratory flow
No difference in QoL
Wolter et al. [18] Azithromycin vs 
placebo; 2 parallel 
groups
n = 59 (age 18–44 years; 
mean 27.9 years) mean 
FEV1 = 56.5%
CRQ Significant difference in 
FEV1 and FVC favouring 
azythromycin
Significant improvement 
in all domains of QoL
Saiman et al. [19] Azithromicyn vs 
placebo; 2 parallel 
groups
n = 185 (age >= 6 years) 
(n= 177 for QoL)
mean age 20 years ≈  
60% had FEV1 > 60%
CFQ Significant difference in 
FEV1, lower risk of 
exacerbation, higher 
weight, but more side 
effects in treatment 
group
Significant difference in 
physical functioning 
domain only
HOME/HOSPITAL 
ANTIBIOTICS
Wolter et al. [20] Home versus hospital 
IVs antibiotics; 2 parallel 
groups
17 adolescents and 
adults
CRQ primary outcome No clinical compromise 
associated with home 
therapy
Home IVs fared worse 
for fatigue and mastery, 
but better for personal, 
family, sleeping, eating 
and total disruption
STEROIDS
Balfour-Lynn et al. [24] Corticosteroids vs 
placebo; crossover
n = 22 (age 7–17 years; 
mean 10.3 years)
mean FEV1= 64% (range 
21% to 102%)
Ad hoc VAS scales No significant benefit in 
any of the outcomes
No changes in well-
being
FEV1 = forced expiratory volume in one second, expressed as percent predicted; FVC = forced vital capacity; QWB = Quality of Well-being Scale; 
CFQ = Cystic Fibrosis Questionnaire; CRQ = Chronic Disease Respiratory Questionnaire; ≈  = approximately. QoL is secondary outcome measure 
unless otherwise indicated. All authors refer to QoL in the title, abstract or paper except [24] who refer to well-being.Health and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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the drug compared with placebo. The only results given
for QoL were: 'The median difference in the visual ana-
logue score (range 0–100) for well being between the end
of the azythromycin and placebo treatment periods was 0,
as was the change in the total quality of well being score'.
It cannot be ascertained whether the use of a CF specific
scale would have detected treatment differences.
Wolter et al. [18] reported data from a parallel design RCT
comparing azythromycin with placebo. Patients took azy-
thromycin 250 mg/day or placebo for three months and
were assessed at baseline and each subsequent month for
lung function, weight and QoL. Quality of life was meas-
ured using the Chronic Respiratory Disease Questionnaire
(CRQ). The CRQ has four subscales: fatigue, mastery,
emotion and dyspnoea which can be summed to provide
a total QoL score. The authors reported that treatment
with azythromycin significantly reduced the rate of
decline in lung function over time. Improvements in the
domains of mastery, emotion, dyspnoea and total score
Table 2: Summary of RCTs in CF measuring QoL: mucolytic therapies, exercise and pancreatic enzymes
Authors Brief description Sample QoL scale used Authors' main 
conclusion
Authors' conclusion 
about QoL outcome
MUCOLYTIC 
THERAPIES
Ranasinha et al. [27] DNase vs placebo; two 
parallel groups
n = 71 (age = 16–55 
years) mean FEV1 ≈  47%
Ad hoc 9-item scale Significant improvement 
in FEV1 but not in FVC
DNase did not improve 
overall well-being but 
improvements in feeling, 
cough frequency and 
chest congestion
Ramsey et al. [28] 3 doses of DNase vs 
placebo; 4 parallel 
groups
n = 181 (age 8–65 
years) mean FEV1 
between 58.6% and 
84.6% for the 4 groups
Ad hoc 9-item scale FEV1 and FVC improved 
across all doses 
compared with placebo
DNase associated with 
decreased dyspnoea and 
improved well-being
Fuchs et al. [29] 2 doses of DNase vs 
placebo; 3 parallel 
groups
n= 968 (age 5–54 years) 
mean FEV1 ≈  60%
Ad hoc 9-item scale Improved lung function 
on DNase
Increase in general well-
being
Wilmott et al. [30] 2.5 mg DNase or 
placebo twice daily
n = 80 children and 
adults (age >5 years; 
mean ≈  20) mean FEV1 ≈  
40%
Ad hoc scale No effect of drug on 
change in FEV1 or FVC
No differences on well-
being scales
Suri et al. [31-33] Open crossover study 
of DNase once daily 2.5 
mg vs alternate day 2.5 
mg and saline
n = 48 (age 7–17 years) 
(n = 40 completed 
study)
QWB-SA No evidence of 
differences between 
active treatments; daily 
treatment better than 
saline for FEV1
No effects
Eng et al. [34] 10 ml of either normal 
or hypertonic saline; 
parallel groups
n = 58 (age 7–26 years) 
mean FEV1≈  52%
Ad hoc VAS of 
perceived change
Significant differential 
improvement from 
baseline in FEV1 for 
hypertonic saline
An improvement, but 
group difference did not 
reach statistical 
significance
EXERCISE
Selvadurai et al. [36] Comparison of aerobic/ 
resistance training and 
standard care; 3 parallel 
groups
n = 66 (age 8–16 years) 
mean FEV1 ≈  57%
QWB Aerobic training better 
for peak aerobic 
capacity. Resistance 
training better for 
weight gain, lung 
function and leg 
strength
Aerobic training 
associated with better 
QoL
Klijn et al. [37] Anaerobic training vs 
normal daily activity; 2 
parallel groups
n = 20 (age 9–18 years; 
mean 14 years) mean 
FEV1 = 75.2% (exercise 
group); 82.1% (control 
group)
Dutch CFQ Anaerobic and aerobic 
performance improved 
in training group, but 
not control group
QoL improved in 
training group but not in 
control group
Orenstein et al. [38] Aerobic versus upper-
body strength training
n = 62 (age 8–18 years) 
Analysis on 53 cases of 
complete data
QWB Strength and aerobic 
training may increase 
upper-body strength, 
and physical work 
capacity
No significant effects
PANCREATIC 
ENZYMES
Gan et al. [39] 4 versus 1 capsule daily 
crossover design
n = 13 (age 19–46 years; 
mean 28 years) mean 
BMI = 21
Symptoms and general 
well-being on 10-point 
scale
No difference between 
treatments
No significant changes in 
scores for well-being
FEV1 = forced expiratory volume in one second, expressed as percent predicted; FVC = forced vital capacity; QWB = Quality of Well-being Scale; 
CFQ = Cystic Fibrosis Questionnaire; BMI= body mass index, ≈  = approximately. QoL is secondary outcome measure unless otherwise indicated. 
All authors refer to QoL in the title, abstract or paper except [34] [39] who refer to well-being.Health and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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were greater for those who received azythromycin.
Improved fatigue scores were only seen in the azythromy-
cin group. Although means and standard deviations of
QoL scores are presented for each treatment group, there
are a high proportion of missing values, and in the
absence of confidence intervals it is difficult to assess the
clinical importance of the results.
Similarly, Saiman et al. [19] described a parallel designed,
placebo-controlled RCT to 'determine any association
between azythromycin and lung function in CF'. Treat-
ment was prescribed (bodyweight <40 kg = 250 mg; >40
kg = 500 mg) on three days each week for six months. QoL
was one of several secondary outcome measures, and was
evaluated using the USA Cystic Fibrosis Questionnaire
(CFQ). Unfortunately, the scale, which is a CF specific
QoL measure, was not described in the paper. The CFQ
child measure is a 33 item self report instrument that
includes three broad domains of QoL: physical symp-
toms, emotional functioning and social functioning and
there are five domains that are specific to CF; body image,
eating disturbances, treatment burden, respiratory symp-
toms and digestive symptoms. The adult version has 48
Items across 12 domains: physical, role, vitality, emotion,
social, body, eating, treatment, health, weight, respiratory
and digestion. The authors presented the QoL results as
'three broad factors' (physical, psychosocial, and body
image) plus a total score. Presumably, these factors were
an amalgamation of domains, although no explanation is
provided as to how they were derived. The authors also
appear to have combined the child and adult versions of
the CFQ but provide no rationale or account of how this
was done. A differential improvement in pulmonary func-
tion and nutritional status was reported for the azythro-
mycin group, but for QoL the only statistically significant
difference reported was for the 'physical factor'. The CFQ
scales are usually scored from 0–100. If this is the case, the
observed difference of 2.7 in the 'physical factor' change
score is unlikely to have clinical importance for the
patient. Even a difference of 5.3, which is the extreme of
the stated 95% confidence interval, is likely to be only
marginally clinically important. Moreover, the small dif-
ference reported can be largely accounted for by an aver-
age deterioration of 1.9 in the placebo group. The
problems of interpretation are exacerbated by a lack of
baseline data on QoL scores.
Home intravenous antibiotic therapy
Home intravenous (IV) therapy is a popular form of treat-
ment. It has the advantages of cost-saving by freeing up
hospital beds and avoiding cross infection; and the
patient and family are able to continue their normal activ-
ities. However, a crucial question is whether patients
would adhere to their treatment sufficiently to ensure that
the home and hospital environments would provide
equivalent outcomes. Wolter et al. [20] conducted a paral-
lel designed RCT of home compared with hospital IVs.
The aim was 'to determine the equivalence of home and
hospital care... so that if no difference was detected
between the two modes of treatment, this could be stated
with confidence'. Those randomised to home therapy
spent 2–4 days in hospital being taught how to prepare
and administer their own antibiotics. Data were obtained
from 17 adolescent and adult patients for 31 admissions
of respiratory exacerbation. Therapy consisted of ceftazi-
dime, 2 g 12 hourly and tobramycin 4–6 mg/kg daily as a
single bolus. QoL was the primary outcome, measured
using the Chronic Respiratory Disease Questionnaire
(CRQ). Patients were assessed on days 0, 10 (cessation of
drug) and 21. On day 21 they were asked to score the
degree of disruption to family, personal, sleeping and eat-
ing aspects of their life on a 7-point scale. The median
duration of treatments was similar for both home and
hospital groups. The authors reported no differences con-
cerning dyspnoea and emotional functioning, but the
fatigue, mastery and total CRQ scores were poorer for
home patients. However, improved QoL was reported in
the areas of personal, family, sleeping, eating and total
disruption for home, compared with hospital admissions.
There were no reported statistical differences in clinical
outcome. QoL scores were the main outcome, but the
study was only powered on the dyspnoea QoL scale. The
sample size calculation, carried out during the study
design, was based on 95% power to detect 'differences of
5 or more units in the dyspnoea score'. The authors
reported that 'a 5 units difference... was hypothesised as
an important change'. Yet after the data had been col-
lected it was clear that the power calculation was invalid,
and the sample too small. The estimated difference in dys-
pnoea change scores was 2.5, but no confidence intervals
were presented. It is likely that a 95% confidence interval
for this difference would contain values greater than 5.
Anti-inflammatory therapy
Lung inflammation can occur very early in life [21] and
corticosteroids have the potential to reduce lung damage
arising from inflammation. These drugs are among the
most potent anti-inflammatory agents available and there
is widespread prescribing of inhaled steroids in CF [22].
Oral corticosteroids are associated with several adverse
effects, although the adverse effects of inhaled steroids are
fewer. However, a Canadian trial was stopped prema-
turely because of the increased frequency of PA  [23].
Because there are perceived and potential benefits and
harms of steroid treatment, QoL measurement is very use-
ful. One such trial was located. Balfour-Lynn et al. [24]
conducted a double blind, placebo-controlled, ran-
domised crossover trial in which fluticasone propionate
(400 ug daily) was given as a dry powder inhaler. The drug
was inhaled for six weeks with a four-week washoutHealth and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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period before crossover. There were several biochemical
and clinical outcome measures. At the beginning and end
of each treatment period, scores for general well-being
and appetite were recorded on a 10 cm visual analogue
scale, in order to establish symptom severity. The authors
concluded that there were no changes in respiratory symp-
toms, well-being or appetite scores. However, there is no
discussion of the clinical importance of the confidence
intervals in what the authors acknowledge is a small and
possibly underpowered study.
Mucolytic therapies
Mucolytic agents enable respiratory secretions to be expec-
torated more easily. Dornase alfa (DNase) is a nebulised
treatment intended for administration prior to chest phys-
iotherapy to maximise chest clearance. Nebulised hyper-
tonic saline is also a potential mucolytic therapy for CF.
This review identified six RCTs of mucolytic therapies that
measured QoL as a secondary outcome. Four of these were
placebo-controlled trials of DNase, one compared DNase
to hypertonic saline and one was a placebo-controlled
trial of hypertonic saline.
Early studies evaluating the effective dosage, biochemical
efficacy and safety of DNase in CF adults, employed a
non-validated ad hoc measure of QoL [25,26]. This com-
prised five questions concerning general well-being (feel-
ing, energy, physical activity, appetite, sleep) and four CF-
related symptoms (cough frequency, cough severity, ease
of sputum expectoration and chest congestion). Patients
reported these items on a five-point Likert response scale.
Additionally, the magnitude of dyspnoea was rated on a
visual analogue scale. Even though there were no data
describing the validity, reliability or sensitivity of the
measure, it was subsequently used in several studies of
DNase. These included the four randomised controlled
trials of DNase reported here.
Ranasinha et al. [27] conducted a double-blind, placebo-
controlled RCT in which patients received either 2.5 mg
DNase twice daily or placebo for 10 days. The authors
reported an improvement in lung function following
DNase therapy. QoL was measured on seven occasions
over the study period of 47 days (including pre-trial and
follow-up). Only baseline QoL scores are reported but the
authors infer that although there was no improvement in
overall well-being or dyspnoea there were improvements
in 'feelings', cough frequency and chest congestion. The
total absence of any QoL change data makes it impossible
for the reader to judge or interpret.
In a double blind placebo-controlled RCT performed by
Ramsey et al. [28] children and adults were recruited. The
trial consisted of four parallel groups (three different
doses of DNase and placebo). The study period was 42
days with medication administered for the first ten
days.Mean percentage change in lung function from base-
line for each treatment group were provided at days 3, 10,
21 and 42. An improvement in lung function was
observed during the administration of DNase, with values
declining towards baseline following the treatment
period. The authors reported a decreased perception of
dyspnoea and an improved perception of well-being in
the DNase groups compared to controls. Voice alteration
and sore throat were more frequent among patients
receiving DNase. However, QoL was not measured past
day 10 so it is unclear whether QoL would have demon-
strated similar trends to those of lung function. No base-
line values are presented for QoL, but mean changes
(from baseline to Day 10) are given for each group, with-
out any measures of variability. There is no discussion of
any possible dose-response (as is presented for FEV1), or
of the clinical importance of the observed differences.
These differences appear to be too small to be clinically
important, and it is difficult to detect any consistent
trends in the dose-response. Problems in interpretation
are exacerbated by the lack of baseline data on QoL. It is
impossible to judge if patients had scope for improve-
ment, whether the scales were sensitive, or whether any
particular dose is to be preferred with respect to QoL.
Fuchs et al. [29] conducted a double-blind, placebo-con-
trolled RCT with three parallel groups (2.5 mg DNase
once or twice daily and placebo). Children and adults
were treated over a six-month period. Both doses of
DNase resulted in slightly improved lung function. The
authors report an increase in general well-being and a
decrease in CF symptoms, although information is not
available concerning specific symptoms of the measure
(e.g. cough frequency). This was a large study and
although the authors reported statistically significant dif-
ferences these do not appear to be clinically important.
There were ceiling effects in QoL measures at baseline: for
each group the mean score was 3.9, with a maximum
score of 5 (ceiling). Although the authors reported that
the average change in well-being score for the once-daily
group was significantly greater than for placebo, this
change is extremely small, and is not replicated in the
twice-daily group. There is therefore little convincing evi-
dence about the effects of the treatments on QoL.
Wilmott et al. [30] undertook a double blind, placebo-
controlled RCT with two parallel groups. Patients received
either 2.5 mg DNase or placebo twice per day for 14 days.
Clinical and QoL data were recorded on days 1, 8 and 15.
Similar changes in lung function occurred in both groups.
The authors reported no differences between the groups
for any of the well-being or CF symptom items, but they
do not provide enough information to enable the reader
to interpret the data. There was evidence of greaterHealth and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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improvement in dyspnoea (measured on the VAS) in the
treatment group. This was statistically significant at day 8,
but not at day 15, although the difference may have still
been clinically important at day 15. This possible treat-
ment effect was not reported in the QoL results, where, for
all scales (including dyspnoea at different levels of activ-
ity) they report 'no difference between the groups'.
DNase is a comparatively expensive treatment for CF and
not all patients can benefit from it. Hypertonic saline is an
inexpensive potential alternative. A comparison of DNase
and hypertonic saline was undertaken by Suri et al [[31-
33] – publications of same trial]. They conducted an open,
randomised crossover trial. Children were randomised to
once daily DNase (2.5 mg), alternate day DNase (2.5 mg)
or twice daily 5 mL 7% hypertonic saline in blocks of 12
weeks' duration with a two week washout period between
treatments. In addition to the efficacy of the three treat-
ments the study aimed to compare cost-effectiveness and
therefore a utility measure of QoL, the Quality of Well-
being Scale-Self Administered (QWB-SA), was chosen.
The QWB-SA contains five domains: acute and chronic
generic symptoms, self care, mobility, physical activity
and performance of usual activities. These domains are
combined to produce a well-being score of between 0
(death) and 1 (symptom-free full function). Parent and
child completed the questionnaire together. The authors
reported no difference in improved lung function
between daily and alternate day DNase (16% and 14%
improvement in FEV1% respectively). A mean FEV1% pre-
dicted improvement of only 3% was observed for the
hypertonic saline condition and a statistically significant
difference was reported between daily DNase and hyper-
tonic saline. There were no significant changes from base-
line for any treatment on the QWB-SA scale; neither were
there differences between the treatment change scores.
The trial was not powered for QoL and in one paper [31]
the authors included confidence intervals. An improve-
ment in reported well-being may be expected to accom-
pany these relatively large changes in lung function in the
DNase groups, yet the authors do not discuss possible rea-
sons for these negative findings.
Eng et al. [34] conducted an open-label, placebo-control-
led, parallel trial. Patients were randomly allocated to
receive 10 ml of either normal saline (0.9% NaCl) or
hypertonic saline (6.0%NaCl) twice daily (nebulised
prior to physiotherapy) for two weeks. Change in lung
function was the primary outcome and patient-perceived
CF related symptoms were a secondary outcome. Patients
rated perceived change of dyspnoea, fatigue, appetite,
exercise tolerance, sleep and general well-being on a 10
cm visual analogue scale (VAS) on days 14 and 28. They
also rated the effectiveness of sputum clearance on a sim-
ilar VAS based on their diary information. Hypertonic
saline improved lung function (at day 14) compared with
normal saline; the mean increase in FEV1% predicted
from baseline was 15% for the hypertonic saline com-
pared with 2.8% for normal saline. The authors reported
that the administration of hypertonic saline significantly
improved exercise and the quality of sleep. For the other
symptoms and general well-being there were no statisti-
cally significant differences between the groups. However,
it is unlikely that the study was adequately powered for
symptoms and well-being scores. While some of the esti-
mated differences may only appear marginally important,
it is probable the 95% confidence intervals for most of the
symptoms and well-being scores would contain clinically
important values. Given this problem, together with a
total lack of information about QoL and symptoms at
baseline, the QoL results are inconclusive.
Exercise
Lung function and exercise tolerance decrease as CF dis-
ease progresses. Exercise training aims to preserve and
improve fitness levels and enable CF patients to perform
everyday activities. Patients with high levels of aerobic fit-
ness have better survival than those with low fitness levels
[35]. Aerobic training aims to improve cardiovascular
function whereas anaerobic or resistance training aims to
improve muscle strength. Three RCTs of exercise measur-
ing QoL as a secondary outcome were located.
Selvadurai et al. [36] conducted an RCT to compare aero-
bic and resistance training. Children, admitted to hospital
for a pulmonary exacerbation, were randomised to one of
three parallel groups; aerobic training, resistance training
and a control group. The mean duration of hospitalisa-
tion was around 19 days for each group. The exercise
groups received five training sessions each week. All
groups received in-patient standard care – intravenous
antibiotics, chest physiotherapy and nutritional supple-
ments. Peak aerobic capacity and lung function appear to
be primary outcomes, measured on admission to hospital
and at discharge. Quality of life, measured by the QWB
scale, was assessed at baseline and one month following
discharge. The authors do not describe the scale, its scor-
ing method, or what the tabulated values represent. They
report that aerobic training was associated with better
peak aerobic capacity, activity levels and QoL, whereas
children who received resistance training had better
weight gain, lung function and leg strength.
Klijn et al. [37] investigated the effects of anaerobic train-
ing in non-hospitalised children who were randomly
assigned to either a training group or control group. The
exercise group trained for 30–45 minutes, twice each week
for twelve weeks. There were several clinical and physio-
logical outcomes. QoL was measured by the Dutch ver-
sion of the Cystic Fibrosis Questionnaire (CFQ). A 47Health and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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item teen/adult scale and a 35 item child scale of the CFQ
were employed but there was no description of the psy-
chometric properties of this recently-translated scale. The
domains of the scales were not described and neither was
the instrument's scoring system. All outcome measures
were evaluated at baseline, at the end of the training
period and at 12 weeks' follow-up. The authors reported
that by the end of the training period the children in the
exercise group had improved their anaerobic and aerobic
performance and QoL. At twelve weeks follow-up anaero-
bic performance and QoL remained higher than pre-train-
ing values. However, for QoL scores there are no direct
statistical tests comparing the groups, and no confidence
intervals. It also appears that data from the CFQ child and
teen/adult scales were incorporated into the same analysis
and it is unclear how this was achieved. There was inade-
quate reporting of summary statistics to enable the reader
to interpret the findings, and selective reporting of QoL
data. The CFQ scales consist of numerous domains but
only the physical functioning domain was statistically sig-
nificant. Even so, the authors conclude that 'anaerobic
training has measurable effects on QoL'. Furthermore, the
interpretation of the physical function data is unreliable
because baseline imbalances in this score were not consid-
ered (training group mean 70.3; control group mean
83.2).
Orenstein et al. [38] conducted a one-year randomised
trial to compare the effects of a home-based, semi-super-
vised, upper-body strength training regimen with a simi-
larly structured aerobic training regimen. Sixty-two
children participated in the trial although analysis was
undertaken on 53 completed cases. Participants in both
exercise conditions were visited at home once per week for
the first eight weeks then monthly for the remainder of the
study. All patients were encouraged to exercise at least
three times per week for a year. Aerobic fitness, pulmo-
nary function, strength and QoL were measured at base-
line, 6 and 12 months. QoL was measured using the
interview format of the QWB scale: for children younger
than 12 years a parent responded. The authors concluded
that strength and aerobic training may increase upper
body strength and that both types of training may increase
physical work capacity. There were no statistically signifi-
cant differences for either within or between group analy-
ses for QoL. Interpretation of results rests on p-values,
with no discussion of clinical importance, although the
reported differences in total well-being score appear to be
too small to be of clinical importance.
Pancreatic enzyme therapy
The majority of CF patients develop pancreatic insuffi-
ciency which leads to the maldigestion of dietary lipid,
protein and carbohydrate. Pancreatic enzyme replace-
ment therapy is used to manage maldigestion with
patients taking numerous capsules each day. Gan et al.
[39] conducted a double-blind, randomised crossover
trial to compare a high lipase pancreatic enzyme prepara-
tion (Pancrease-HL) with regular Pancrease capsules. The
rationale was that if the same strength of pancrease could
be put into 1 capsule instead of 4, adherence to treatment
may improve. Thirteen adults participated in two study
periods of 14 days. During each period patients took 5
capsules 3 times per day; either 4 of Pancrease and 1 of
placebo or 1 of Pancrease-HL and 4 placebo. The primary
outcome measures appear to be mean fat and nitrogen
excretion. General well-being was measured daily on a ten
point scale. The authors reported no differences between
the groups for any outcome. It is unclear whether the
scores presented are baseline or change scores, or if the
daily ratings were combined in some way to calculate the
well-being scores. The authors' conclusion is that one cap-
sule of the new preparation appears to be 'equivalent' to
four capsules of the regular preparation, which suggests
that the design should have been an equivalence study.
However, in the absence of a clear hypothesis for the
study, or a sample size calculation it is difficult to be sure.
Whatever the hypothesis, the possible lack of power
means that confidence intervals are essential for valid
interpretation of results.
Discussion of QoL data from CF trials
The value of the evidence from a trial depends on the
quality of its design. Much of the data presented here was
difficult to interpret. There are several reasons for this, and
these are presented in this discussion.
Choice of QoL measure
Only a few papers provided a rationale for measuring QoL
[14,20,30,31] or a rationale for the choice of QoL
instrument [18,20,30,31]. A variety of scales, reported to
measure QoL, were employed: a uni-dimensional global
rate of change questionnaire [14],'ad hoc' CF rating scales
[24,27-30,34,39], the Quality of Well-being Scale
[17,31,36,38], the Chronic Respiratory Disease Question-
naire [18,20], and the American [19] and Dutch [37] ver-
sions of the Cystic Fibrosis Questionnaire. The fact that a
scale has been previously used on a CF population does
not mean that it has been appropriately validated for use
in CF studies. Apart from CF specific QoL instruments
[40,41] only the SF-36 [42,43] and the Chronic Respira-
tory Disease Questionnaire (CRQ) [44] have undergone
appropriate psychometric testing in CF. A chosen scale
should be relevant to the participants, disease and inter-
vention. It is also important that a scale is sensitive to
change, otherwise a negative finding could be an artefact
of the insensitivity of the scale and not of the real effect of
the treatment on QoL. It may be more ethical not to meas-
ure QoL at all than to use an inappropriate scale which
could give misleading results.Health and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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Quality of reported data
In order for readers to assess the importance of RCT find-
ings, it is essential to have adequate descriptions of the
outcomes and data. CONSORT recommends: 'Authors
should give full details of how the primary and secondary
outcomes were measured' and 'for each primary and sec-
ondary outcome, a summary of results for each group and
the estimated effect size and its precision (e.g. 95% confi-
dence interval)'.
Description of scale and scoring methods
Some papers gave neither a full description of the scale
nor an explanation of the scoring method
[17,19,30,36,37,39]. Several studies included children
but it is not always clear whether the child, parent or a
combination responded. Irrespective of the difficulties
encountered with the interpretation of a combination of
patient and patient proxy data, it is useful to know from
whom the data have been obtained. A comprehensive
description of the scale and scoring methods is particu-
larly important in cases where scales have been merged
across child and adult versions [19,37] or the scale trans-
formed [38]. One paper stated that two scales with differ-
ent numbers of items and domains had been combined
but did not justify this or describe how it had been done
[37]. While the statistical power is likely to be increased by
such pooling, there is no guarantee that it is clinically
meaningful.
Baseline data
QoL outcomes are often secondary, and a RCT may not
have been powered on them. It is therefore important that
adequate summary information is provided. A table of
baseline characteristics, by treatment group, allows read-
ers to judge the success of the randomisation. There may
be clinically important baseline differences between the
groups, or ceiling or floor effects. In several papers it was
impossible to assess the validity of the conclusions, as
there was incomplete summary information about QoL
baseline values [17,19,20,28,34,37].
Statistical versus clinical significance
It is important to distinguish between statistical signifi-
cance and clinical significance. This is addressed in the
CONSORT statement as follows: 'The difference between
statistical significance and clinical importance should
always be borne in mind. Authors should particularly
avoid the common error of interpreting a non-significant
result as indicating equivalence of interventions. The con-
fidence interval provides valuable insight into whether the
trial result is compatible with a clinically important effect,
regardless of the p-value'. Most statistical tests will give a
confidence interval for the difference, as well as a p-value.
A 95% confidence interval gives a range of values, which
we can be 95% sure contains the true difference. When the
p-value is greater than 0.05, and the 95% confidence
interval contains no values of any clinical importance, it is
reasonable to conclude that any real difference between
treatments is too small to be of any interest. If a study is
too small then the observed difference may be too small
to reach statistical significance, even in the presence of a
genuine difference in treatments. Conversely, in large
studies, small changes in both FEV1 and QoL scores may
be statistically significant as determined by a p-value but
the observed differences may be too small to be clinically
relevant. In this review there was a tendency for QoL
results to be interpreted in terms of statistical significance.
Of the two papers where QoL was the main outcome,
Quittner [14] provided a full description of the data,
whereas Wolter [20] gave no confidence intervals or meas-
ures of variability. Only three studies in which QoL was a
secondary outcome reported confidence intervals
[19,24,31] even though the studies were not powered on
the QoL outcome. Most reported standard deviations or
standard errors but three gave no description of variability
[17,27,39]. Overall, there was little or no discussion of
QoL results when they were statistically non-significant.
Neither was there adequate discussion of the relationship
between QoL results and those for the primary outcomes.
Types of trials, sample size and QoL
Superiority trials
It is important that an RCT has adequate power. The
majority of RCTs are superiority trials, where the aim is to
test whether one treatment is better than another (or than
placebo). CONSORT states: 'Ideally a study should be
large enough to have a high probability (power) of detect-
ing a statistically significant or clinically important differ-
ence of a given size if such a difference exists'... 'Reports of
studies with small samples frequently include the errone-
ous conclusion that the intervention groups do not differ,
when too few patients were studied to make such a claim'.
In this review some papers did not report a formal sample
size calculation for any outcome [24,28,38,39]. One study
[24] reported a retrospective power calculation based on
the observed data, which is of little value [8]. No study
had an a priori sample size calculation for QoL when this
was a secondary outcome.
Crossover trials
In some circumstances using a crossover design can allevi-
ate the problem of requiring a large sample. Four crosso-
ver trials were located [17,24,31,39]. Crossover trials are
useful where the effect of a treatment can be switched on
and off, and it is ethical to do this. When feasible they can
be more efficient than parallel-group designs because
each participant acts as his/her own control and a smaller
sample is required for the same statistical power. How-
ever, although a great deal might be known about the
pharmacological effect of a drug in the body and its con-Health and Quality of Life Outcomes 2005, 3:19 http://www.hqlo.com/content/3/1/19
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sequent effect on lung function, much less is understood
about possible carryover effects on QoL. This is poten-
tially compounded in studies where there are more than
two treatment periods.
Non-inferiority trials
There are instances in which the aim is not to demonstrate
superiority of one treatment over another, but to show
therapeutic equivalence i.e. that one treatment is not infe-
rior to another. The methods used for superiority trials are
then of no use; failure to find a statistically significant dif-
ference is not the same as establishing equivalence. In fact,
it is impossible to show 'exact' equivalence, so researchers
have to define the range of values, near zero, that are of no
clinical interest. This value of 'no difference' must, logi-
cally, be less than the minimal clinically important differ-
ence (MCID). For example, if the MCID for a QoL scale is
10 points a difference of 3 units between groups would
probably be classed as 'equivalent'; it may be less clear
how to view a difference of 7 units. This is a clinical deci-
sion, not a statistical one, and the values need to be estab-
lished before the sample size calculation is done. For the
two cases in this review where equivalence designs were
apparently employed [20,39] there was either a lack of
precision in the aim of the trial, or an inappropriate anal-
ysis. In the one trial where QoL was the primary outcome
[20], the sample size calculation was not presented in
terms of equivalence, and was revised after data were col-
lected. This resulted in a retrospective adjustment to the
definition of what had been deemed to be a clinically
important difference. There was no sample size calcula-
tion in the other study [39].
Missing values
Many RCTs suffer problems with missing values. These
can be sporadic (e.g. where a patient misses an appoint-
ment or omits to return one questionnaire) or because of
dropout, where data are completely missing after a certain
time. This can be a common problem in QoL measure-
ment and researchers have to decide how to deal with
incomplete data. One way is to omit cases with missing
values. If values are missing 'completely at random', then
analysis on the complete data can be valid, although it is
against the principle of 'intention to treat'. However, miss-
ingness is more often related to a change in condition
[45]. In practice it is very difficult to be sure that values are
missing completely at random, simply because the values
are unknown.
The implications of missing data are potentially serious if
about 15% or more of the values are missing, or if there
are different patterns of missingness between treatment
groups. When there is a significant amount of missing
data it is highly desirable to check the sensitivity of the
results by using more than one statistical method. There
are a variety of methods that can handle incomplete data.
Different methods give potentially different results,
because they make different assumptions about the rea-
sons for missingness. Some methods are relatively simple
(e.g. use the last recorded value) but p-values and confi-
dence intervals should really be adjusted. Methods like t-
tests and repeated measures ANOVA require complete
data. However, there are more sophisticated methods like
Generalised Estimating Equations (GEEs) that can be used
to analyse longitudinal data with different numbers of
observations per participant. Nonetheless, the fact that the
analysis is possible does not mean that it is valid.
Researchers should compare participants with and with-
out missing data to check for potential systematic differ-
ences. Most papers reported missing observations for the
QoL outcomes, some of which were substantial
[18,31,38]. Only Suri [31] gave any description of drop-
outs and checked that they were not the most severely
affected participants. Orenstein [38] omitted dropouts
from the analysis because of potential bias, but did not
explore the nature of the dropouts and the possible bias
resulting from their exclusion. Some researchers used
GEEs for their analysis [18,31,38] but gave incomplete
details of the chosen options.
Conclusion
Authors tend to provide definite statements about QoL,
but no trial in this review provided conclusive data. Even
well-designed clinical trials can be difficult to manage,
and high-quality reporting is essential. In the papers in
this review the treatments and patient characteristics were
generally well described. Difficulties arose when QoL
scales were not described and summary information was
not provided. Journal editors place word restrictions on
papers so full descriptions of all secondary outcomes are
not always possible. However, interpretation was further
confounded when the emphasis was purely based on sta-
tistical significance ignoring clinical relevance. Although
the CONSORT statement is an excellent guide for RCTs, it
was not available when some of the trials were reported,
and it does not specifically address QoL assessment and
psychometric validity [46]. Properly validated disease-
specific QoL measures are most appropriate for the evalu-
ation of CF therapies as they include the relevant items
that are likely to be sensitive to change [47]. Without suit-
able guidelines it is difficult for authors to employ QoL
scales appropriately. This review highlights many of the
pitfalls of QoL measurement in CF clinical trials and pro-
vides constructive information concerning QoL in trial
design and the reporting of QoL data.
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